Common presentations of haematological diseases {#s0010}
===============================================

An abnormal blood count or blood cell morphology does not necessarily indicate a primary haematological problem because it may reflect an underlying non-haematological condition or may be the result of therapeutic interventions. Anaemia occurs in many conditions, but a primary blood disease should be considered when a patient has splenomegaly, lymphadenopathy, a bleeding tendency or thrombosis and/or nonspecific symptoms characteristic of leukaemias and lymphomas (malaise, sweats or weight loss).

As with any clinical problem, the first steps in determining the diagnosis include obtaining a careful clinical and drug history and thorough physical examination. The result of these, in combination with the patient\'s age, sex, ethnic origin, social and family history and knowledge of the locally prevalent diseases, will determine subsequent laboratory investigations.

Initial screening tests {#s0015}
=======================

Although the range of haematological tests available to support clinical and public health services is broad, it is often the simplest investigations that are most useful in indicating the diagnosis. Even poorly-resourced laboratories are usually able to provide an initial panel of tests such as haemoglobin concentration (Hb), white blood cell count (WBC) and platelet count (Chapter 26) and examination of a peripheral blood film for a differential leucocyte count (Chapter 3) and cellular morphology (Chapter 5). These screening tests will often enable the underlying pathological processes to be suspected promptly and point to a few key diagnostic tests. The investigation of specific haematological problems is covered in detail in Chapters 9 (iron deficiency anaemia), 10 (megaloblastic anaemia), 11, 12 and 13 (haemolytic anaemias), 14 (haemoglobinopathies) and 18, 19 and 20 (coagulation disorders)Chapter 9Chapter 10Chapter 11Chapter 12Chapter 13Chapter 14Chapter 15Chapter 16Chapter 17Chapter 18Chapter 19Chapter 20.

 {#s0020}

### Interpretation of Screening Tests {#s0025}

Results of laboratory screening tests should always be interpreted with an understanding of the limitations of the tests and the physiological variations that occur with sex, age and conditions such as pregnancy and exercise. Physiological variations in cell counts are detailed in Chapter 2. Abnormalities of red cells, white cells or platelets may be quantitative (increased or reduced numbers) or qualitative (abnormal appearance and/or function).

Quantitative Abnormalities of Blood Cells {#s0030}
-----------------------------------------

### Increased Numbers of Cells {#s0035}

#### Increases affecting more than one cell line {#s0040}

A simultaneous increase in the cells of more than one cell line suggests overproduction of cells originating in an early precursor cell. This occurs in myeloproliferative neoplasms in which one cell type may predominate, e.g. platelets in essential thrombocythaemia and red cells in polycythaemia vera, but there are often increases in other cell lines. The diagnosis will depend on which cell line dominates.

### Erythrocytosis {#s0045}

Patients with a persistently (e.g. \>2 months) raised venous haematocrit (Hct) (\>0.52 l/l males, \>0.48 l/l females) should be assessed to determine the cause of the apparent polycythaemia. Erythrocytosis can be relative or absolute and, if absolute, primary or secondary.*Relative*: normal total red cell volume with reduced plasma volume*Absolute*: males and females with Hct values above 0.60 and 0.56 l/l, respectively, can be assumed to have an absolute erythrocytosis and do not require confirmatory studies.[@bb0010] However, the reason for the elevation must still be elucidated.*Primary*: this is usually polycythaemia vera (PV), part of the spectrum of myeloproliferative neoplasms. Rarely, it is inherited, due to mutation of genes involved with erythropoietin or its receptor.*Secondary*: to chronic hypoxia (e.g. chronic lung disease, congenital heart disease, high-affinity haemoglobins) or aberrant erythropoietin production.

Secondary polycythaemia can generally be excluded by the clinical history and examination, assessment of serum erythropoietin concentration and arterial oxygen saturation, haemoglobin electrophoresis plus oxygen dissociation curve and abdominal ultrasound examination. The presence of splenomegaly is suggestive of PV and this diagnosis can be confirmed by demonstrating the *JAK2* V617F mutation, which is present in 95% of patients.[@bb0015] Only if this mutation (or one of the much less common *JAK2* exon 12 mutations) is not detected is the measurement of total red cell and plasma volume necessary (Chapter 17).

### Leucocytosis {#s0050}

#### Neutrophilia {#s0055}

Neutrophils are commonly increased during pregnancy and in acute infections, inflammation, alcohol intoxication, corticosteroid therapy and acute blood loss or red cell destruction. Neutrophilia with the neutrophils showing heavy cytoplasmic granulation ('toxic' granulation) is a common finding in severe bacterial infections. In the absence of any underlying cause, a high neutrophil count with immature myeloid cells suggests chronic myelogenous leukaemia (CML); cytogenetic and molecular studies to look for t(9;22) and the *BCR--ABL1* fusion gene are indicated (Chapter 8).

#### Lymphocytosis {#s0060}

Lymphocytosis is a feature of certain infections, particularly infections in children. It may be especially marked in pertussis, infectious mononucleosis, cytomegalovirus infection, infectious hepatitis, tuberculosis and brucellosis. Lymphocytosis is also a common transient reaction to severe physical stress. Elderly patients with lymphoproliferative disorders, including chronic lymphocytic leukaemia and lymphomas, often present with lymphadenopathy and a lymphocytosis. Morphology and immunophenotyping of the cells combined with histological examination of a bone marrow trephine biopsy specimen (and if necessary other tissue biopsy) are used to classify these disorders and to give an indication of management and prognosis.[@bb0020] It is occasionally difficult to differentiate between a reactive and a neoplastic lymphocytosis. In this situation, immunophenotyping, to provide evidence of light chain restriction and polymerase chain reaction for immunoglobulin or T-cell receptor gene rearrangements, may indicate the presence of a monoclonal population of lymphocytes, thereby supporting a diagnosis of neoplastic, rather than reactive, lymphoproliferation. If lymph nodes are enlarged, a lymph node biopsy for histology and immunohistochemistry may be helpful in diagnosis.

#### Monocytosis {#s0065}

A slight to moderate monocytosis may be associated with some protozoal, rickettsial and bacterial infections including malaria, typhus and tuberculosis. High levels of monocytes (monocyte count \>1 × 10^9^/l) in an elderly patient suggest chronic myelomonocytic leukaemia or, sometimes, atypical chronic myeloid leukaemia. Because these conditions fall into the myelodysplastic/myeloproliferative neoplasm group of disorders,[@bb0025] the diagnosis would be supported by finding splenomegaly, quantitative and qualitative abnormalities in other cell lines or a clonal cytogenetic abnormality.

#### Eosinophilia {#s0070}

Eosinophilia is typically associated with allergic disorders including drug sensitivity, skin diseases and parasitic infections. In most cases, the cause is indicated by the clinical history, which should include details of all medications and foreign travel, and by examination of the stool and urine for parasites, cysts and ova. A diagnosis of chronic eosinophilic leukaemia is made if there is dominant eosinophilia with an increase in blast cells in the blood or marrow, or cytogenetic or molecular evidence of an abnormal myeloid clone.[@bb0030] If no other cause for eosinophilia is found it is important, because of the therapeutic implications (i.e. responsiveness to imatinib), to confirm or exclude a diagnosis of eosinophilic leukaemia related to rearrangement of *PDGFRA* or *PDGFRB* (see [p. 559](#s0265){ref-type="sec"}).[@bb0035] The idiopathic hypereosinophilic syndrome is an unusual cause of eosinophilia in which release of the contents of eosinophil granules results in damage to the heart, lungs and other tissues. It is defined by the presence of a peripheral blood eosinophil count of 1.5 × 10^9^/l or greater for at least 6 months with resultant tissue damage. This is a diagnosis of exclusion, made only when detailed investigations exclude other possible causes of eosinophilia including systemic mastocytosis, eosinophilic leukaemia and eosinophilia associated with a phenotypically aberrant T-cell population or a neoplastic clone of T cells.

#### Basophilia {#s0075}

Basophilia as an isolated finding is unusual. However, it is a common feature of myeloproliferative neoplasms and basophils may be particularly prominent in chronic myelogenous leukaemia. In this condition, an increasing basophil count may be the first indication of accelerated phase disease.

### Thrombocytosis {#s0080}

Thrombocytosis is often associated with infectious and inflammatory conditions such as osteomyelitis and rheumatoid arthritis. Haematological causes of thrombocytosis include chronic blood loss, red cell destruction, splenectomy and rebound following recovery from marrow suppression. Under these circumstances, a moderately increased platelet count (e.g. 400--800 × 10^9^/l) does not usually have any pathological implications. Primary thrombocythaemia is usually the result of a myeloproliferative neoplasm; rarely, it is an inherited condition. When there is isolated persistent thrombocytosis in a myeloproliferative neoplasm the diagnosis is essential thrombocythaemia (as long as a *BCR--ABL1* fusion gene has been excluded). Thrombotic or haemorrhagic complications can occur but often the diagnosis is an incidental one.[@bb0040] A significant proportion of individuals with essential thrombocythaemia have the *JAK2* V617F mutation, which is associated with an increased risk of thrombosis.[@bb0045] The criteria for this diagnosis are discussed on [p. 559](#s0265){ref-type="sec"}.

### Reduced Numbers of Cells {#s0085}

#### Reductions in more than one cell line {#s0090}

A reduction in cell numbers occurs because of increased destruction, reduced production or increased pooling in the spleen or other organs. Reduced production of cells may be the result of aplastic anaemia, a lack of haematinics such as folate or vitamin B~12~ or interference with normal haemopoiesis by infiltration (e.g. leukaemia, lymphoma, multiple myeloma, metastatic carcinoma -- often with secondary myelofibrosis), infection (e.g. HIV infection, tuberculosis, leishmaniasis) or exposure to toxins (e.g. alcohol) or myelosuppressive drugs (e.g. hydroxycarbamide or methotrexate). Certain myeloid neoplasms, e.g. primary myelofibrosis and MDS, are characterized by cytopenias, which are at least in part the result of ineffective haemopoiesis. Cytopenia is also sometimes a feature of acute myeloid leukaemia (AML), when it is due both to ineffective haemopoiesis and to replacement of normal haemopoietic stem cells by leukaemic cells. A relatively common cause of a global reduction in circulating cells is pooling of the cells in a markedly enlarged spleen (hypersplenism), which may be secondary to conditions such as primary myelofibrosis and portal hypertension. Examination of a bone marrow aspirate and trephine biopsy specimen is often helpful in determining the cause of cytopenias for which no obvious cause is apparent

### Anaemia {#s0095}

The mechanisms which result in anaemia are decreased production, reduced red cell lifespan, blood loss and splenic pooling. Anaemia is broadly divided into three types: microcytic (low MCV), macrocytic (high MCV) and normocytic (normal MCV). The choice of investigations is guided by the MCV and red cell morphology in addition to clinical features. [Figure 23.1](#f0010){ref-type="fig"}, [Figure 23.2](#f0015){ref-type="fig"}, [Figure 23.3](#f0020){ref-type="fig"} are flow charts that provide an orderly sequence of investigations for the different types of anaemia on the basis of these indices. Examination of a blood film will usually suggest the quickest route to the diagnosis; confirmation may require the more specific tests, which are given in the text. The presence of basophilic stippling in a patient with microcytic red cells suggests thalassaemia trait or, much less often, lead poisoning. A dimorphic blood film is typical of congenital sideroblastic anaemia but is more often the result of iron deficiency responding to treatment. Pappenheimer bodies suggest that a microcytic anaemia is the result of sideroblastic erythropoiesis.Figure 23.1Investigation of a microcytic hypochromic anaemia. HbEP, Hb electrophoresis; HPLC, high-performance liquid chromatography.Figure 23.2Investigation of a macrocytic anaemia. MDS, myelodysplastic syndrome.Figure 23.3Investigation of a normocytic, normochromic anaemia.

### Microcytic Anaemia {#s0100}

The most common cause of anaemia worldwide is iron deficiency, which can be suspected from a low MCV ([Fig. 23.1](#f0010){ref-type="fig"}) and the presence of hypochromic, microcytic red cells. Laboratory confirmation of iron deficiency may be based on measurements of serum ferritin, serum iron plus either total iron-binding capacity or transferrin assay, red cell protoporphyrin and staining of bone marrow aspirates for iron (see Chapter 4). Assay of soluble transferrin receptors has good sensitivity and specificity for iron deficiency and may be useful in the presence of inflammation when interpretation of ferritin levels is difficult.[@bb0050] A diagnosis of iron deficiency must be followed by a search for the cause. This should include specific questions relating to blood loss and dietary insufficiency and may require stool examination for parasites and occult blood, endoscopic examination of the gastrointestinal tract to exclude occult malignancy and tests for coeliac disease. The differential diagnosis of iron deficiency anaemia includes anaemia of chronic disease. Clinical and laboratory features of inflammation or chronic infection may suggest this diagnosis, which is confirmed by demonstration of normal or high serum ferritin and reduced serum iron, transferrin and iron-binding capacity.

The thalassaemias also cause microcytosis, but both α and β thalassaemia trait are usually associated with an increased red blood cell count (RBC) and a normal or near-normal Hb despite a considerable reduction of the MCV and MCH. In contrast, in iron deficiency the MCV and MCH do not fall until the Hb is significantly reduced. Further investigations, such as high-performance liquid chromatography (HPLC) or haemoglobin electrophoresis supplemented by measurement of Hb A~2~ and Hb F usually confirm the diagnosis of β thalassaemia trait. The diagnosis of α thalassaemia trait is more difficult; detection of infrequent Hb H inclusions is usually possible in α^0^ thalassaemia trait, but definitive diagnosis requires DNA analysis.[@bb0055] A diagnosis of α^0^ thalassaemia heterozygosity can be clinically important for prediction of haemoglobin Bart\'s hydrops fetalis since, if both parents have α^0^ thalassaemia, this very serious condition can occur in a fetus. DNA analysis is therefore indicated when a pregnant woman of appropriate ethnic origin has an MCH of \<25 pg. Hb H inclusions may not be detected in α^+^ thalassaemia trait but this diagnosis is of less clinical importance and confirmation is thus not usually required.

### Macrocytic Anaemia {#s0105}

A high MCV ([Fig. 23.2](#f0015){ref-type="fig"}) with oval macrocytes and hypersegmented neutrophils suggests folate or vitamin B~12~ deficiency and is an indication for assays of these vitamins (see Chapter 10); subsequent investigations could include malabsorption studies, tests for coeliac disease and tests for intrinsic factor and gastric parietal cell antibodies. In patients with these blood film findings and normal vitamin assays, haematinic deficiency is not completely excluded and further investigation is indicated. A Schilling test permits a definitive diagnosis of pernicious anaemia but currently this test is not available due to a lack of reagents. In the absence of intrinsic factor antibodies, the diagnosis of pernicious anaemia may be presumptive. Pernicious anaemia is commonly associated with autoimmune thyroid disease and other autoimmune disorders, such as diabetes mellitus. A high MCV may also be associated with alcohol excess and liver disease or use of drugs such as hydroxycarbamide or zidovudine. Macrocytosis resulting from chronic haemolysis is associated with increased numbers of immature red cells, which appear slightly larger and bluer than normal red cells (polychromatic macrocytes) on a Romanowsky-stained peripheral blood film. Supravital staining of blood films (see p. 33) or an automated reticulocyte count can be used to confirm reticulocytosis. Untreated anaemia associated with polychromasia is likely to indicate blood loss or haemolysis. The combination of red cell fragments, thrombocytopenia and polychromasia indicates a microangiopathic haemolytic anaemia and should trigger further tests such as a platelet count, coagulation studies, assessment of renal function and a search for infection or neoplastic disease. This further assessment is urgent because these may be features of thrombotic thrombocytopenic purpura, which requires immediate treatment by plasma exchange.

### Normocytic Anaemia {#s0110}

Normochromic, normocytic anaemia ([Fig. 23.3](#f0020){ref-type="fig"}) is frequently the result of an underlying chronic, non-haematological disease. Investigations should include screening for renal insufficiency, subclinical infections, autoimmune diseases and neoplasia. In the presence of anaemia, a lack of polychromasia, confirmed by reticulocytopenia, points toward a primary failure of erythropoiesis or lack of compensatory increased red cell production in blood loss or haemolysis. Examination of the bone marrow may be helpful in demonstrating haematological causes for a normochromic, normocytic anaemia such as aplastic anaemia or MDS.[@bb0060] Staining for iron may also show that there is a block in iron metabolism suggestive of anaemia associated with chronic inflammatory disease.

### Leucopenia {#s0115}

#### Neutropenia {#s0120}

Once physiological variation, ethnicity and familial or cyclic neutropenia have been excluded (see p. 19), the non-haematological causes of isolated neutropenia to be considered include overwhelming infection, autoimmune disorders such as systemic lupus erythematosus, irradiation, drugs (particularly anticancer agents) and large granular lymphocyte leukaemia. Bone marrow examination may assist in determining whether the problem is the result of peripheral destruction (increased marrow myeloid precursors) or stem cell failure (lack of marrow myeloid precursors). Typical marrow appearances occur in drug-induced neutropenia, in which there is a relative paucity of mature neutrophils and in Kostmann\'s syndrome (infant genetic agranulocytosis) where there is maturation arrest at the promyelocytic stage.

#### Reduced numbers of lymphocytes, monocytes, eosinophils and basophils {#s0125}

Lymphocytes, eosinophils and basophils may all be reduced by physical stress such as surgery, trauma and infection. Lymphopenia with neutrophilia is a common combination of haematological abnormalities in severe acute respiratory syndrome and in many other patients with acute illness or trauma. Lymphopenia, especially affecting the CD4 cells, may occur in HIV infection and renal failure. Monocytopenia (\<0.2 × 10^9^/1) is typically found in hairy cell leukaemia, which is also associated with pancytopenia, typical bone marrow histology and lymphocytes with a characteristic cytology and immunophenotype.

### Thrombocytopenia {#s0130}

Thrombocytopenia is a common isolated finding and it is important to ensure that the laboratory result reflects a true reduction in platelet count before embarking on further diagnostic tests. Frequent causes of spurious thrombocytopenia include blood clots in the sample, platelet aggregation and platelet satellitism. Platelet aggregation, which is seen on the blood film, may occur *in vitro* as the result of a temperature-dependent or anticoagulant-dependent autoantibody or on slides that have been made directly from a finger prick sample. True thrombocytopenia is most frequently the result of autoantibodies (autoimmune 'idiopathic' thrombocytopenic purpura), HIV infection, anticancer chemotherapy, other drugs (such as thiazide diuretics), alcohol excess, hypersplenism and MDS (in the elderly). The blood film should be examined for giant or hypogranular platelets, red cell fragments, May--Hegglin inclusions in leucocytes and abnormal cells that might indicate leukaemia or lymphoma. The clinical circumstances, together with blood film and bone marrow examination, usually enable the various causes of thrombocytopenia to be differentiated. An association with thrombosis, disturbed renal or hepatic function and haemolytic anaemia, should prompt investigations for other diseases such as thrombotic thrombocytopenic purpura and, in a pregnant woman, the HELLP (haemolysis + elevated liver enzymes + low platelet count) syndrome. A bone marrow examination is often carried out early in the investigation of thrombocytopenia because it is helpful in excluding conditions such as acute leukaemia, which occasionally present with isolated thrombocytopenia.

### Pancytopenia {#s0135}

Pancytopenia (reduction in the WBC, Hb and platelet count) is most often the result of anticancer chemotherapy, HIV infection, hypersplenism and bone marrow infiltration or failure. Careful examination of a blood film is important if the reason for the pancytopenia is not apparent from the clinical history. If this does not reveal the cause, bone marrow aspiration and trephine biopsy may be needed.

Qualitative Abnormalities of Blood Cells {#s0140}
----------------------------------------

In health, only the most mature forms of cells appear in the peripheral blood. Cells at various stages of immaturity, such as nucleated red blood cells, polychromatic red cells, myelocytes and metamyelocytes, may be released from the bone marrow in conditions where the bone marrow is overactive (e.g. acute haemolytic states or recovery from suppression) or functionally abnormal. Their presence in the peripheral blood indicates that active haemopoiesis is taking place.

### Abnormalities of All Cell Lines {#s0145}

The combination of anisopoikilocytosis, mild macrocytosis, hypogranular neutrophils with abnormal nuclear morphology and platelet anisocytosis, often with quantitative abnormalities, is virtually pathognomonic of MDS. These features are reflected in the bone marrow with disturbance of the normal developmental pathway and sometimes nuclear:cytoplasmic asynchrony. Cytogenetic studies are helpful for confirming the diagnosis, especially when cytological abnormalities are minor, and can also assist in determining the prognosis.

### Abnormalities of Individual Cell Lines {#s0150}

#### Red cells {#s0155}

Congenital abnormalities of the red cell affecting the structure (e.g. spherocytosis, elliptocytosis) and content (e.g. haemoglobinopathies, enzymopathies) often produce typical morphological changes (see Chapter 5). The type of changes will guide further investigations toward analysis of structural proteins, haemoglobin electrophoresis or HPLC, or enzyme assays. Acquired red cell abnormalities may also help to indicate underlying pathology. For example, target cells may prompt investigation of liver function, whereas increased rouleaux formation may indicate the need for investigations for multiple myeloma or inflammatory conditions.

#### White cells {#s0160}

Congenital abnormalities of neutrophils are unusual, but similar morphological abnormalities (e.g. Pelger--Huët cells) may be seen in acquired conditions such as MDS. Reactive changes in lymphocytes, including basophilic, faceted cytoplasm, are typically seen in infectious mononucleosis, which can be diagnosed using an appropriate serological screening test (see p. 105) or, if this is negative, by demonstration of immunoglobulin M (IgM) antibodies to the Epstein--Barr virus. These atypical lymphocytes can sometimes be difficult to differentiate from circulating lymphoma cells. Bone marrow histology, combined with immunophenotyping studies and determination of lymphocyte clonality by demonstration of light chain restriction or by gene rearrangement studies, may be needed to reach a firm conclusion.

#### Platelets {#s0165}

Platelets that function poorly may not necessarily appear morphologically abnormal, although sometimes they are hypogranular or larger than normal. A normal platelet count with an abnormal *in vitro* platelet function test is characteristic of a disorder of platelet function, but some patients with abnormal platelet function are also thrombocytopenic. Hereditary disorders of platelet function are uncommon and usually present as a bleeding diathesis. When a qualitative disorder of platelets is suspected, platelets should be examined to assess size and to detect the cytological features of the grey platelet syndrome. Qualitative disorders of platelets can broadly be divided into two categories: abnormalities of the platelet membrane (e.g. Bernard--Soulier syndrome, Glanzmann\'s thrombasthenia) and abnormalities of platelet secretory function (e.g. storage pool diseases). Acquired disorders of platelet function are more common than inherited disorders. Haematological conditions associated with platelet dysfunction include myeloproliferative neoplasms, MDS and dysproteinaemias (in plasma cell neoplasms). Many widely prescribed drugs, including aspirin and non-steroidal anti-inflammatory agents, interfere with platelet function. Systemic conditions, particularly chronic renal failure and cardiopulmonary bypass, are also associated with a bleeding tendency as a result of qualitative platelet defects. Most of these acquired functional defects are not associated with any abnormality in platelet appearance but in MDS and, to a lesser extent, in the myeloproliferative neoplasms, there may be hypogranular and giant platelets.

Specific tests for common haematological disorders {#s0170}
==================================================

Common haematological disorders are outlined in the following sections with suggestions for investigations that may be helpful in confirming the diagnosis. The lists are not intended to be exhaustive because the range of tests provided locally will depend on the availability of expertise and technology. The investigations discussed are those that are likely to be available within a general haematology department.

Red Cell Disorders {#s0175}
------------------

### Microcytic Hypochromic Anaemias {#s0180}

For more information, see Chapters 9 and 14.•Measurement of serum ferritin or iron plus total iron-binding capacity or transferrin assay, red cell protoporphyrin or soluble transferrin receptors•Bone marrow aspirate with staining for iron•Stool examination for occult blood•Gastrointestinal imaging and endoscopy, with biopsies if appropriate; rarely, blood loss studies with ^51^Cr-labelled red cells•Tests for malabsorption•Serological tests for coeliac disease (e.g. endomysial antibodies, tissue transglutaminase antibodies)•Serum lead (if lead poisoning is suspected)

If thalassaemia is suspected:•Haemoglobin electrophoresis plus Hb A~2~ and Hb F measurements or HPLC•Haemoglobin H preparation•Family studies•DNA analysis (when the diagnosis is clinically important).

### Macrocytic Anaemias {#s0185}

If macrocytic, megaloblastic erythroid maturation is demonstrated, further investigations should be undertaken as described in Chapter 10. If the blood film is typical of megaloblastic anaemia, relevant assays and further investigations can often indicate the diagnosis without the need for a bone marrow aspirate. Macrocytosis may also be secondary to conditions such as alcohol excess, liver disease, MDS, hydroxycarbamide administration and hypothyroidism. Reticulocytosis from any cause can also increase the MCV.

### Aplastic Anaemia[@bb0060] {#s0190}

•Vitamin B~12~ and folate assays•Viral studies, particularly for Epstein--Barr, HIV and hepatitis viruses•Bone marrow aspirate and trephine biopsy including cytogenetic analysis•Flow cytometry for glycosylphosphatidylinositol-anchored proteins[\*](#fn0010){ref-type="fn"} to detect a paroxysmal nocturnal haemoglobinuria (PNH) clone (urine examination for haemosiderin if positive)•Peripheral blood gene mutation analysis for dyskeratosis congenita if there are relevant clinical features or lack of response to immunosuppressive therapy.

If Fanconi\'s anaemia is suspected:•Studies of sensitivity of chromosomes to breakage by DNA cross-linking agents.

### Haemolytic Anaemias {#s0195}

A haemolytic process may be suspected by the presence of a falling Hb, a reticulocytosis and jaundice with an increase in unconjugated bilirubin level (see Chapters 9, 10 and 11Chapter 9Chapter 10Chapter 11).

White Cell Disorders {#s0200}
--------------------

The blood film is often of critical importance in the differential diagnosis of white cell disorders though it may sometimes be normal (e.g. in some patients with lymphoma or neutrophil functional defects). Changes in white cell numbers or morphology may occur rapidly in response to local or systemic disorders. In chronic leukaemias, bone marrow aspiration may add little to the diagnosis, but the pattern of infiltration of neoplastic cells seen on trephine biopsy can have diagnostic value or prognostic significance, e.g. in lymphoma and chronic lymphocytic leukaemia.

### Acute Leukaemia {#s0205}

•Full blood count and peripheral blood film•Bone marrow aspirate (trephine biopsy if bone marrow aspirate is inadequate)•Blood or marrow immunophenotyping, unless obviously myeloid, or in all patients if it is to be used for monitoring minimal residual disease (cytochemical stains can be used if immunophenotyping is not readily available)•Cytogenetic analysis•Molecular studies (e.g. fluorescence *in situ* hybridization -- FISH -- analysis) for detection of all patients with acute lymphoblastic leukaemia (ALL) with hyperdiploidy or *ETV6--RUNX1* fusion, detection of *BCR--ABL1* fusion in adults with ALL and detection of other mutations of specific oncogenes, e.g. *NPM1*, *CEBPA* and possibly *FLT3* in AML.

### Neutropenia {#s0210}

•Vitamin B~12~ and folate assays•Autoantibody screen including rheumatoid factor and investigations for systemic lupus erythematosus•Serial neutrophil counts for cyclical neutropenia•Tests for anti-neutrophil antibodies•Bone marrow aspirate and trephine biopsy•Flow cytometry for PNH (see aplastic anaemia above)•Consider the need for investigation for an abnormal T-cell population.

### Chronic Myelogenous Leukaemia {#s0215}

•Full blood count and peripheral blood film•Bone marrow aspirate•Cytogenetic analysis•Molecular studies (e.g. real-time quantitative reverse transcriptase or FISH) for *BCR--ABL1* transcripts•Neutrophil alkaline phosphatase score (only if cytogenetic and molecular genetic analysis are not available).

### Chronic Lymphoproliferative Disorders/Lymphadenopathy {#s0220}

Diagnosis may be made from various specimens including lymph nodes, bone marrow aspirates, trephine biopsy cores and peripheral blood and other fluids such as cerebrospinal fluid, ascitic fluid and pleural aspirates.[@bb0065] •Full blood count and peripheral blood film•Serum protein electrophoresis and immunoglobulin concentrations•Plasma uric acid, calcium and lactate dehydrogenase (LDH)•Serological screening for infectious mononucleosis, cytomegalovirus infection, HIV infection and toxoplasmosis (if infectious cause suspected) and human T-cell leukaemia/lymphoma virus, when clinically relevant•Bone marrow aspirate and trephine biopsy (to demonstrate the presence and distribution of abnormal lymphocytes) and/or lymph node or other tissue biopsy•Flow cytometry immunophenotyping or immunohistochemistry of biopsy specimens•Cytogenetic or molecular genetic analysis including investigation for immunoglobulin heavy chain or T-cell receptor gene rearrangement if the diagnosis of lymphoma is in doubt•Imaging (plain radiographs, ultrasonography, computed tomography scan, magnetic resonance imaging).

### Myelomatosis (Plasma Cell Myeloma) {#s0225}

•Full blood count and peripheral blood film[@bb0070]•Serum protein electrophoresis, immunofixation and quantification of immunoglobulins and any paraprotein•Urine electrophoresis and immunofixation for Bence--Jones protein (early morning urine sample and, if positive, quantification on 24 h collection)•Serum free light chain quantification and ratio•Serum albumin, tests of renal function, plasma uric acid, calcium, phosphate and alkaline phosphatase measurements•β~2~ microglobulin quantification•Plasma viscosity•Bone marrow aspirate (with cytogenetic or FISH analysis if results will influence treatment decisions, and flow cytometry immunophenotyping or DNA analysis if these analyses are to be used for monitoring minimal residual disease)•Trephine biopsy•Radiological skeletal survey.

Other Disorders {#s0230}
---------------

### Myeloproliferative Neoplasms {#s0235}

•Full blood count and blood film•Vitamin B~12~ (or B~12~-binding capacity)•Uric acid assay•Serum erythropoietin assay•*JAK2* mutation analysis if PV, ET or primary myelofibrosis is suspected•Arterial oxygen saturation and carboxyhaemoglobin level (selected patients only)•Abdominal ultrasound examination•Bone marrow aspirate and trephine biopsy•Cytogenetic analysis•Neutrophil alkaline phosphatase (only if other more specific tests are unavailable)•Red cell and plasma volume (selected patients only).

If splenectomy is contemplated:•Ferrokinetic and red cell survival studies•Spleen scan and red cell pool measurement.

### Myelodysplastic syndromes {#s0240}

•Full blood count and blood film•Bone marrow aspirate and trephine biopsy•Cytogenetic analysis.

### Pancytopenia with Splenomegaly {#s0245}

•Vitamin B~12~ and folate assays•Serum rheumatoid factor and autoantibody screen•Bone marrow aspirate and trephine biopsy•Examination of bone marrow or splenic aspirate for amastigotes of *Leishmania donovani* and bacterial culture of marrow for infectious agents including *Mycobacterium tuberculosis*•Biopsy of palpable lymph nodes•Liver biopsy•Tests for paroxysmal nocturnal haemoglobinuria (see p. 291).

The rationale behind these tests and details of specialized investigations can be found in comprehensive haematology textbooks, in electronic databases and on websites.

Classification of haematological neoplasms {#s0250}
==========================================

Previous classifications for haematological neoplasms have now been largely supplanted by the World Health Organization\'s Classification of Tumours of Haematopoietic and Lymphoid Tissues,[@bb0020] which outlines the international standards for assessment and diagnosis of haematological neoplasms. Application of the WHO criteria requires the results of history and physical examination, morphology (cytology or histology), immunophenotyping, cytogenetic analysis and, in some circumstances, molecular genetic analysis. The French--American--British (FAB) group classifications (see previous editions) continue to have a place (a) when these techniques are not all available and (b) in making a provisional morphological diagnosis, e.g. in acute leukaemia, while awaiting the results of further tests. Whichever classification is used the criteria should be strictly observed so that there is consistency between different centres and countries. To avoid confusion, FAB terminology (e.g. M1, M2) should not be applied if the WHO classification is being used. Details of the FAB classifications can be found in specialized textbooks.[@bb0075]

The WHO classification of haematological neoplasms has several major categories ([Table 23.1](#t0010){ref-type="table"} )Table 23.1WHO classification of myeloid neoplasms and acute leukaemias[@bb0080]Myeloproliferative neoplasms (MPN)Myeloid and lymphoid neoplasms associated with eosinophilia and abnormalities of *PDGFRA*, *PDGFRB* or *FGFR1*Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)Myelodysplastic syndrome (MDS)Acute myeloid leukaemia and related neoplasmsAcute leukaemias of ambiguous lineageB lymphoblastic leukaemia/lymphomaT lymphoblastic leukaemia/lymphoma

Classification of Acute Myeloid Leukaemia {#s0255}
-----------------------------------------

The WHO classification categorizes cases as AML ([Table 23.2](#t0015){ref-type="table"} ) if the following criteria are met:1.There are at least 20% of blast cells of myeloid lineage in the blood or bone marrow *or*2.If the erythroid cells are at least 50% of bone marrow cells, blast cells are at least 20% of non-erythroid cells *or*3.Primitive erythroid cells constitute at least 80% of bone marrow cells *or*4.There is a myeloid sarcoma (granulocytic sarcoma) *or*5.One of a number of specified chromosomal rearrangements is present. Table 23.2WHO Classification of acute myeloid leukaemia and related neoplasms[@bb0080]Therapy-related myeloid neoplasmsAcute myeloid leukaemia with recurrent genetic abnormalities AML with t(8;21)(q22;q22); *RUNX1-RUNX1T1* AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); *CBFB-MYH11* APL with t(15;17)(q22;q12); *PML-RARA* AML with t(9;11)(p22;q23); *MLLT3-MLL* AML with t(6;9)(p23;q34); *DEK-NUP214* AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); *RPN1-EVI1* AML (megakaryoblastic) with t(1;22)(p13;q13); *RBM15-MKL1* *Provisional entity: AML with mutated NPM1* *Provisional entity: AML with mutated CEBPA*Acute myeloid leukaemia with myelodysplasia-related changesAcute myeloid leukaemia, not otherwise specified AML with minimal differentiation AML without maturation AML with maturation Acute myelomonocytic leukaemia Acute monoblastic/monocytic leukaemia Acute erythroid leukaemia Pure erythroid leukaemia Erythroleukaemia, erythroid/myeloid Acute megakaryoblastic leukaemia Acute basophilic leukaemia Acute panmyelosis with myelofibrosisMyeloid sarcomaMyeloid proliferations related to Down syndrome Transient abnormal myelopoiesis Myeloid leukaemia associated with Down syndromeBlastic plasmacytoid dendritic cell neoplasm

It should be noted that the WHO classification is hierarchical. If appropriate, cases are first assigned to the category of therapy-related leukaemia. Next, cases are assigned, if appropriate, to the category of AML with recurrent genetic abnormalities. Cases continue to be assigned to successive categories in the order shown in [Table 23.2](#t0015){ref-type="table"}, with remaining cases finally being categorized as 'AML not otherwise specified.' This final group is further subdivided into categories resembling those of the FAB classification (but defined in quite a different manner). Blastic plasmacytoid dendritic cell neoplasm and myeloid neoplasms associated with Down syndrome are recognized as specific entities.

The WHO classification of acute leukaemia[@bb0080] lists cytogenetic abnormalities that, in combination with ≥20 blasts, indicate a diagnosis of AML with myelodysplasia-related changes; assignment to this category can also be based on a previous history of MDS or on morphological evidence of dysplasia.

Classification of the Myelodysplastic Syndromes {#s0260}
-----------------------------------------------

The WHO classification of MDS ([Table 23.3](#t0020){ref-type="table"} ) requires evidence for a myeloid neoplasm with ineffective and, generally, dysplastic haemopoiesis; blasts must be \<20% in both blood and bone marrow ([Table 23.4](#t0025){ref-type="table"} ). It will be noted that cytogenetic analysis is essential for the application of the WHO classification because cases of the 5q− syndrome cannot otherwise be recognized. Like the classification of AML, this is a hierarchical classification. Therapy-related MDS is categorized with therapy-related AML. Remaining cases are then assessed as to whether they meet the criteria for the 5q− syndrome. If they do not, they are assigned to the remaining categories, depending on the number of lineages showing dysplasia, the percentage of ring sideroblasts, the presence or absence of Auer rods and the percentage of blast cells in the blood and marrow. The WHO classification differs from the FAB classification in not regarding chronic myelomonocytic leukaemia as MDS; instead it assigns it to the MDS/MPN group.Table 23.3WHO Classification of the myelodysplastic syndromes (MDS) (2008)Refractory cytopenia with unilineage dysplasia Refractory anaemia Refractory neutropenia Refractory thrombocytopeniaRefractory anaemia with ring sideroblastsRefractory cytopenia with multilineage dysplasia (with or without ring sideroblasts)Refractory anaemia with excess blastsMyelodysplastic syndrome with isolated del(5q)Myelodysplastic syndrome, unclassifiableChildhood myelodysplastic syndrome *Provisional entity: refractory cytopenia of childhood*Table 23.4WHO diagnostic criteria for the myelodysplastic syndromes (MDS)DiseaseBlood findingsBM findingsRefractory cytopenia with unilineage dysplasia (RCUD): (refractory anaemia \[RA\]; refractory neutropenia \[RN\]; refractory thrombocytopenia \[RT\])Unicytopenia or bicytopenia[a](#tf0010){ref-type="table-fn"}\
No or rare blasts (\<1%)[b](#tf0015){ref-type="table-fn"}Unilineage dysplasia: ≥10% of the cells in one myeloid lineage\
\<5% blasts\
\<15% of erythroid precursors are ring sideroblastsRefractory anaemia with ring sideroblasts (RARS)Anaemia\
No blasts≥15% of erythroid precursors are ring sideroblasts\
Erythroid dysplasia only\
\<5% blastsRefractory cytopenia with multilineage dysplasia (RCMD)Cytopenia(s)\
No or rare blasts (\<1%)[b](#tf0015){ref-type="table-fn"}\
No Auer rods\
\<1 × 10^9^/l monocytesDysplasia in ≥10% of the cells in ≥2 myeloid lineages (neutrophil and/or erythroid precursors and/or megakaryocytes)\
\<5% blasts in marrow\
No Auer rods\
±15% ring sideroblastsRefractory anaemia with excess blasts-1 (RAEB-1)Cytopenia(s)\
\<5% blasts[b](#tf0015){ref-type="table-fn"}\
No Auer rods\
\<1 × 10^9^/l monocytesUnilineage or multilineage dysplasia\
5--9% blasts[b](#tf0015){ref-type="table-fn"}\
No Auer rodsRefractory anaemia with excess blasts-2 (RAEB-2)Cytopenia(s)\
5--19% blasts[c](#tf0020){ref-type="table-fn"}\
Auer rods ±[c](#tf0020){ref-type="table-fn"}\
\<1 × 10^9^/l monocytesUnilineage or multilineage dysplasia\
10--19% blasts[c](#tf0020){ref-type="table-fn"}\
Auer rods ±[c](#tf0020){ref-type="table-fn"}Myelodysplastic syndrome -- unclassified (MDS-U)Cytopenias\
≤1% blasts[b](#tf0015){ref-type="table-fn"}Unequivocal dysplasia in \<10% of cells in one or more myeloid lineages when accompanied by a cytogenetic abnormality considered as presumptive evidence for a diagnosis of MDS (see [Table 23.6](#t0035){ref-type="table"})\
\<5% blastsMDS associated with isolated del(5q)Anaemia\
Usually normal or increased platelet count\
No or rare blasts (\<1%)Normal to increased megakaryocytes with hypolobated nuclei\
\<5% blasts\
Isolated del(5q) cytogenetic abnormality\
No Auer rods[^1][^2][^3]From Vardiman et al (2009).[@bb0080]

Classification of Acute Lymphoblastic Leukaemia {#s0265}
-----------------------------------------------

The WHO classification requires that an acute leukaemia be positively shown to be lymphoid before it is categorized as ALL. This classification groups together ALL and lymphoblastic lymphoma, using the designations precursor B lymphoblastic leukaemia/lymphoblastic lymphoma and precursor T lymphoblastic leukaemia/lymphoblastic lymphoma. These designations are clearly too cumbersome to use in clinical practice and undoubtedly haematologists will continue to refer to 'acute lymphoblastic leukaemia.' The FAB classification of ALL is now redundant except that FAB L3 morphology, i.e. the presence of 'blast cells' with basophilic cytoplasm and vacuolation, is of considerable clinical significance and should be recognized. In most, but not all, of these cases the cells are immunologically mature, expressing surface membrane immunoglobulin and the condition represents a leukaemic presentation of Burkitt lymphoma. The WHO categorization of such cases as lymphoma is more appropriate than their being categorized as ALL and is clinically important because the treatment, which is urgent, differs very considerably from the treatment of ALL.

Classification of Myeloproliferative Neoplasms and Related Conditions {#s0270}
---------------------------------------------------------------------

The WHO classification of myeloproliferative neoplasms (previously called 'disorders') and related conditions ([Table 23.5](#t0030){ref-type="table"} ) is increasingly taking account of cytogenetic or molecular genetic analyses.Table 23.5Myeloproliferative neoplasms (MPN) and related conditions[@bb0030][@bb0035][@bb0080][@bb0085]Myeloproliferative neoplasms Chronic myelogenous leukaemia Polycythaemia vera Essential thrombocythaemia Primary myelofibrosis Chronic neutrophilic leukaemia Chronic eosinophilic leukaemia, not otherwise categorized Mast cell disease MPN, unclassifiableLymphoid and myeloid neoplasms associated with rearrangement of *PDGFRA*, *PDGFRB* or *FGFR1* Lymphoid and myeloid neoplasms associated with rearrangement of *PDGFRA* Myeloid neoplasms associated with rearrangement of *PDGFRB* Lymphoid and myeloid neoplasms associated with rearrangement of *FGFR1*

WHO criteria for a diagnosis of essential thrombocythaemia are: platelet count ≥450 × 10^9^/l; megakaryocyte proliferation with large and mature megakaryocytes on examination of the bone marrow with little or no granulocyte or erythroid proliferation; not meeting WHO criteria for CML, PV, primary myelofibrosis, MDS or other myeloid neoplasm; demonstration of *JAK2* V617F or other clonal marker or no evidence of reactive thrombocytosis.[@bb0085]

WHO criteria for a diagnosis of primary myelofibrosis are divided into major criteria (e.g. megakaryocyte proliferation and atypical megakaryocytes accompanied by reticulin and/or collagen fibrosis; demonstration of *JAK2* V617F or other clonal marker; no evidence of reactive marrow fibrosis; not meeting WHO criteria for CML, PV, MDS or other myeloid neoplasm) and minor criteria (e.g. leukoerythroblastosis; increased serum LDH; anaemia; palpable splenomegaly).

WHO criteria for a diagnosis of systemic mastocytosis are highly complex.[@bb0020] A trephine biopsy with a mast cell tryptase stain is often crucial in the diagnosis. Molecular analysis for a *KIT* mutation can also be important.

Recognition of lymphoid and myeloid neoplasms associated with rearrangement of *PDGFRA*, *PDGFRB* or *FGFR1* requires cytogenetic analysis (for detection of translocations likely to indicate rearrangement of *PDGFRB* or *FGFR1*) and molecular analysis (for detection of the *FIP1L1−PDGFRA* fusion gene that results from a cryptic deletion at 4q12). Appropriate molecular analysis may be either FISH or reverse transcription polymerase chain reaction (RT-PCR). The diagnosis of chronic eosinophilic leukaemia, not otherwise specified, requires exclusion of rearrangement of these three specific genes.

The categorization of neoplasms with features of both myelodysplasia and myeloproliferation and their diagnostic criteria are listed in [Table 23.6](#t0035){ref-type="table"} .Table 23.6Summary of the World Health Organization categories of myelodysplastic/myeloproliferative neoplasmsCategoryCriteriaChronic myelomonocytic leukaemia (CMML)A Ph-negative, *BCR--ABL1*-negative disorder with monocyte count \>1 × 10^9^/lFewer than 20% blasts plus promonocytes in peripheral blood (PB) or bone marrow (BM)Either dysplasia of one or more myeloid lineages or alternative criteria met (acquired clonal cytogenetic abnormality or monocytosis persisting for at least 3 months and alternative causes of monocytosis excluded)Atypical chronic myeloid leukaemia (aCML)A Ph-negative, *BCR--ABL1*-negative disorder with leucocytosis resulting from an increase in neutrophils and their precursors, the precursors (promyelocyte to metamyelocytes) constituting a least 10% of PB white cellsBasophils \<2% of white cellsMonocytes \<10% of white cellsHypercellular BM with granulocytic hyperplasia and dysplasia, with or without dysplasia of other lineagesFewer than 20% blasts plus promonocytes in peripheral blood or bone marrowJuvenile myelomonocytic leukaemia (JMML)A Ph-negative, *BCR--ABL1*-negative disorder with monocyte count \>1 × 10^9^/lFewer than 20% blasts plus promonocytes in peripheral blood or bone marrowPlus two or more of the following Haemoglobin F increased for age Immature granulocytes in the PB WBC \>10 × 10^9^/l Clonal chromosomal abnormality (monosomy 7 not excluded) GM-CSF hypersensitivity of myeloid precursors *in vitro*Myelodysplastic/myeloproliferative neoplasm, unclassifiableA myelodysplastic/myeloproliferative disorder in which the criteria of one of the myelodysplastic syndromes are metThere are prominent proliferative features (e.g. a platelet count of ≥450 × 10^9^/l or a white cell count of ≥13 × 10^9^/l)The condition has developed *de novo*The criteria for other MDS/MPD (CMML, aCML and JMML) are not metThere is no Philadelphia chromosome, *BCR--ABL1* fusion gene, 5q−, inv(3)(q21q26) or t(3;3)(q21;q26)

The Ham test and sucrose lysis test are less sensitive and less quantitative than flow cytometry in the detection of PNH clones and when flow cytometry is available they have generally been abandoned as diagnostic tests for PNH.

[^1]: Bicytopenia may occasionally be observed. Cases with pancytopenia should be classified as MDS-U.

[^2]: If the marrow myeloblast percentage is \<5% but there are 2--4% myeloblasts in the blood, the diagnostic classification is RAEB-1. Cases of RCUD and RCMD with 1% myeloblasts in the blood should be classified as MDS-U.

[^3]: Cases with Auer rods and \<5% myeloblasts in the blood and \<10% in the marrow should be classified as RAEB-2. Although the finding of 5--19% blasts in the blood is, in itself, diagnostic of RAEB-2, cases of RAEB-2 may have \<5% blasts in the blood if they have Auer rods or 10--19% blasts in the marrow or both. Similarly, cases of RAEB-2 may have \<10% blasts in the marrow but may be diagnosed by the other two findings, Auer rod + and/or 5--19% blasts in the blood.
